LP
ASND icon

LMR Partners’s Ascendis Pharma A/S ASND Stock Holding History

LMR Partners’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$1.36M – 1286
2024
Q2 		$1.36M Buy
+10,000
New +$1.36M 0.01% 618

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LMR Partners's ASND Position: Q1 2025 in Review

LMR Partners sold out of Ascendis Pharma A/S (ASND) in Q1 2025, closing a stake of 3,100 shares — an estimated $427K sold.

LMR Partners first reported a position in ASND in Q2 2024 and held it in 3 quarters. The position peaked at $1.36M in Q2 2024. 244 funds tracked by Wall St. Rank hold ASND as of Q1 2025.

  • LMR Partners reported no remaining Ascendis Pharma A/S position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 3,100 Ascendis Pharma A/S shares in Q1 2025, an estimated $427K.
  • LMR Partners first reported a position in Ascendis Pharma A/S in Q2 2024 and held it in 3 quarters.
  • LMR Partners's Ascendis Pharma A/S position peaked at $1.36M in Q2 2024.
  • 244 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.